东菱克栓酶治疗急性进展型脑梗死的临床研究

Clinical studies of Batroxobin in the treatment of acute evolving cerebral infarction

目的 研究东菱克栓酶 (Batroxobin)治疗急性进展型脑梗死的临床效果及其安全性。方法 5 5例急性颈内动脉系统进展型脑梗死患者随机分为治疗组和对照组。 2组均以低分子右旋糖酐静脉滴注作为基础治疗。治疗组加用东菱克栓酶静脉滴注 ,首剂量为 10BU ,以后隔日给予 5BU ,共 2 5BU ;对照组加用盐酸川芎嗪注射液静脉滴注。结果 治疗组患者终止病情继续进展的时间明显早于对照组。从治疗后第 3天开始 ,治疗组临床神经功能缺损评分 (neuro functiondeficitscore ,NFD)明显优于对照组 (P =0 .0 44 ) ,至治疗后第14天 ,两组NFD评分相差更显著 (P =0 .0 0 1)。治疗组血纤维蛋白原水平降低显著 ,不良反应轻微。结论 东菱克栓酶可比较迅速地终止急性进展型脑梗死患者的病情进展 ,明显加快其神经功能的康复 ,而且治疗时间窗宽广 ,安全性良好。

Objective To study the efficacy and safety of Batroxobin in the treatment of acute evolving cerebral infarction. Methods Fifty five cases of acute evolving cerebral infarction were randomly divided into treatment group and control group. The patients in each group were treated with Dextran as the basic management. Batro xobin was added to the treatment group, with the first dose of 10 BU,then,5 BU was given every other day until a total dose of 25 BU. Ligustrazini Hydrochloridum was added to the control group. Results The end of progression of infarction in the treatment group were significantly earlier than that in the control group. From 3 days onward, the neuro function deficit score(NFD) in the treatment group was better than that in the control group( P =0.044), and this difference was increased ( P =0.000)at 14 days. The serum fibrinogen level was decreased significantly in the treatment group. Conclusion Batroxobin can provide favourable effect for ending off the progression for patients with acute evolving cerebral infarction and promote the recovery of the neurofunction of the patient.